Business Context and Reporting Period
This Form 8-K is filed by Virios Therapeutics, Inc. (not Dogwood Therapeutics, Inc., as noted in the metadata request) on May 9, 2024. The filing serves to announce the results of operations for the first quarter ended March 31, 2024. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol VIRI.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data. It references a press release (Exhibit 99.1) for the actual figures. Consequently, the following metrics are not provided in this document:
- Revenue
- Net Profit/Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not disclose specific material changes in financial performance or operations compared to the prior period. It only confirms that the Q1 2024 results have been issued via a press release.
Guidance, Outlook, and Risks
No specific guidance, outlook, management commentary, or risk factors are detailed in this 8-K text. The document explicitly states that the information furnished (including the press release) is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings.
Investor Verification Checklist
- Verify Company Name: Confirm the filing is for Virios Therapeutics, Inc. (VIRI), not Dogwood Therapeutics.
- Review Exhibit 99.1: Access the attached press release to obtain actual Q1 2024 financial figures (revenue, cash burn, net loss).
- Check Liquidity: Review the press release for updates on cash reserves and runway, as this is critical for clinical-stage biotech firms.
- Confirm Filing Status: Note that the financial data in the press release is "furnished" and not "filed," which may affect legal liability interpretations.